Clinical Study

Mk7902-012- A Phase 3 Multicenter, Randomized, Double-Blinded, Active-Controlled, Clinical Study To Evaluate The Safety And Efficacy Of Lenvatinib (E7080/Mk-7902) With Pembrolizumab (Mk-3475) In Combination With Transarterial Chemoembolization (Tace) Vers

Posted Date: Sep 4, 2020

  • Investigator: Olugbenga Olowokure
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

The purpose of this study is to evaluate the efficacy and safety of lenvatinib and pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in participants with incurable, non-metastatic hepatocellular carcinoma (HCC). The primary hypotheses are that pembrolizumab plus lenvatinib in combination with TACE is superior to placebo plus TACE with respect to progression-free survival (PFS) and overall survival (OS)


To Be Eligible: Must Have A Confirmed Diagnosis Of Hcc, Adequately Controlled Blood Pressure With Or Without Antihypertensive Medications, Adequate Organ Function, Not Currently A Candidate For Liver Transplantation, No Uncontrolled Ascites, No Significant Cardiovascular Impairment Within 12 Month


Liver Cancer, Hepatocellular Carcinoma

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.